Ascendis Pharma A (ASND) Share-based Compensation (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Share-based Compensation data on file, last reported at $35.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 32.19% year-over-year to $35.5 million; the trailing twelve-month figure through Mar 2026 stood at $140.2 million (up 25.78% YoY), and the FY2025 full-year result was $135.2 million, up 30.81% from the prior year.
• Share-based Compensation advanced to $35.5 million in Q1 2026, from $34.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $35.8 million in Q3 2025 to a low of $13.6 million in Q3 2022.
• A 5-year average of $24.2 million and a median of $22.4 million in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 34.44% in 2023 and jumped 63.7% in 2024, its largest moves.
• Tracing ASND's Share-based Compensation over 5 years: stood at $14.2 million in 2022, then climbed by 20.93% to $17.1 million in 2023, then jumped by 63.7% to $28.0 million in 2024, then gained by 24.44% to $34.9 million in 2025, then increased by 1.92% to $35.5 million in 2026.
• Business Quant data shows ASND's Share-based Compensation at $35.5 million in Q1 2026, $34.9 million in Q4 2025, and $35.8 million in Q3 2025.